AYUSH Ministries Patangari’s Claim

Yesterday, Baba Ramdev’s Patanjali launched Coronil, a drug claiming to be treatable COVID-19 (New Coronavirus Infection) (# If there is no character limit, add parentheses when first appearing It brings spirit and hope to many people’s hearts. However, just a few hours after the launch, Ayurveda, Unani, Siddha, Homeopathy (AYUSH) Ban on advertising and promotion of Patanja Liu Yurveda. According to the ministry, the facts of allegation and details of the alleged scientific research are unknown. Read again- Two shots of AstraZeneca’s COVID-19 vaccine may be a pandemic solution

The ministry instructed Patanjali to provide all details as soon as possible, including alleged drug names and compositions COVID treatment, Site/hospital, COVID-19, protocol, sample size, institutional ethics committee approval, CTRI enrollment and findings data have been researched and issues have been formally suspended from promoting/publishing such claims. Until considered. The ministry also requested the relevant Utrakhand Oblast state agencies to provide a copy of the license for the drug and details of the product approval. Read again- COVID-19: How to wear a face mask during the hot summer months

This is not a good sign for the company. This means that the sale of this drug is pending. According to Patanjalli, the two drugs “Coronil” and “Swasilverty” treated 69% of COVID-19-positive patients at the end of 3 days and 100% succeeded after 7 days. .. management. The company also said that Clinical trial Held in several cities including Delhi, Meerut and Ahmedabad. Read again- COVID-19 Live Update: Indian cases jump to 4,56,183 due to 14,476 deaths

AYUSH Ministry Opposition Reasons

Meanwhile, the AYUSH ministry issued a statement showing that Patangari proceeded with the promotion without maintaining the drug loop. This clearly violated the order regarding the investigation dated 21 April 2020. COVID drug.. The order requires that all organizations evaluate the ministry before promoting drug promotion for COVID-19. The statement also mentions another order dated April 1, 2020, and is specifically prohibited from advertising as a “false statement” regarding COVID-19-related treatment in television, printed matter, and electronic media. .. Doing this will lead to penalties based on the guidelines of the National Disaster Management Agency. The ministry is currently requesting Pattani to immediately provide the drug composition, test protocol, sample size, as well as details, including test results.

Patanjali’s Missing Link

Patagonia Yurveda claimed to have found a cure for COVID-19, but no medical institution was able to guarantee that claim. Meanwhile, press-related scientists reportedly said the outcome of the trial had not yet been announced. According to the study supervisor, 100 COVID-19-positive patients were recruited to the study. Fifty of them were given the drug and five dropped out along the way. The remaining 50 were given placebo. According to them, 69% of the 45 patients were negative on day 3. Half of the patients who received placebo recovered. As a result, 31 patients who received the drug were negative, and 25 patients were placebo Test negative. There were no other details such as patient profile, severity of symptoms, age of participants, or whether the patient was on any other medication prior to enrollment.

What the clinical trial registry reveals

The clinical trial registry, which requires all trials to be registered, is Asymptomatic, Mild symptomatic, moderate symptomatic, and 15-80 years. The original purpose of the study was to check the patient’s condition on days 3, 7, and 14 to determine if the drug improved immunological parameters. I don’t know. The drugs used in this study were Tablet Swasalis (500 mg), Tablet Pure Ashwagandha Extract (500 mg), Tablet Pure Aziroy Extract (500 mg), Tablet Pure Tulsi Extract (500 mg), Anutile (nasal drops). is.

Release Date: June, 24th, 2020 12:16pm